Quality of Life in NSCLC Survivors — A Multicenter Cross-Sectional Study

Abstract

Introduction: The objective was to assess quality of life (QoL) in lung cancer survivors, compare it to the general population, and identify factors associated with global QoL, physical functioning, emotional functioning, fatigue, pain, and dyspnea. Methods: Data from NSCLC patients who had survived 1 year or longer after diagnosis were collected crosssectionally in a multicenter study. QoL was assessed with the European Organisation for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 and the lung cancer module QLQ-LC13 across different clinical subgroups and compared to age-and sex-standardized general population reference values. Multivariable linear regression analyses were performed to test the associations of patient-, tumor-, and treatmentrelated factors with the six primary QoL scales. Results: Six hundred fifty-seven NSCLC patients participated in the study with a median time since diagnosis of 3.7 years (range, 1.0-21.2 years). Compared to the age-and sex-standardized general population, clinically meaningful differences in the QoL detriment were found on almost all domains: lung cancer survivors had clinically relevant poorer global QoL (10 points, p < 0.001). Whereas in 12 months or longer treatment-free patients this detriment was small (8.3), it was higher in patients currently in treatment (16.0). Regarding functioning and symptom scales, respective detriments were largest for dyspnea (41 points), role function (33 points), fatigue (27 points), social function (27 points), physical function (24 points), and insomnia (21 points) observed across all subgroups. The main factor associated with poorer QoL in all primary QoL scales was mental distress (b j19-31j, all p < 0.001). Detriments in QoL across multiple primary QoL scales were also observed with current treatment (b j8-12j, p < 0.01),

Combination of icotinib and chemotherapy as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: A randomized controlled study

“…Fifthly, health-related quality of life should be assessed for patients with cancer in addition to efficacy and safety analysis of treatments. It is essential to ensure that any clinical gains do not come at the expense of intolerable reductions in quality of life [40]. Further studies should explore the quality of life of lung cancer patients with treatments.…”

Ten-Year Trends of Utilization of Palliative Care Services and Life-Sustaining Treatments and Hospital Costs Associated With Patients With Terminally Ill Lung Cancer in the United States From 2005 to 2014

“…1 Many patients with lung cancer have high symptom burdens such as breathlessness, cancer cachexia, intractable pain, and psychological disorders at their end-of-life (EOL) stage. 3 With the current oncologic consideration, high symptom burden and hospital mortality among patients result in the need for early palliative care intervention. 4,5 Palliative care is well recognized as an optimal comprehensive approach for critically ill patients, particularly during EOL stage.…”

“…1 Many patients with lung cancer have high symptom burdens such as breathlessness, cancer cachexia, intractable pain, and psychological disorders at their end-of-life (EOL) stage. 3…”

Health‐related quality of life and treatment modality among esophageal squamous cell carcinoma survivors: A prospective study using time to deterioration model analysis

“…2 Despite advancing knowledge of the mechanisms of carcinogenicity and improvement in diagnosis and treatment, ESCC prognosis remains poor. 3 Health-related quality of life (HRQOL) is an integral part of clinical, epidemiological, and health economic research, 4 and is increasingly recognized as an important outcome in oncology. 5 However, previous studies have mainly focused on baseline HRQOL data, and only a few have used longitudinal HRQOL data to investigate its association with treatment modality (surgery alone or surgery with adjuvant chemotherapy).…”